A within‐subject comparison of 6‐[18F]fluoro‐m‐tyrosine and 6‐[18F]fluoro‐L‐dopa in Parkinson's disease
Identifieur interne : 001829 ( Main/Exploration ); précédent : 001828; suivant : 001830A within‐subject comparison of 6‐[18F]fluoro‐m‐tyrosine and 6‐[18F]fluoro‐L‐dopa in Parkinson's disease
Auteurs : Catherine L. Gallagher [États-Unis] ; Bradley T. Christian [États-Unis] ; James E. Holden [États-Unis] ; Onofre T. Dejesus [États-Unis] ; Robert J. Nickles [États-Unis] ; Laura Buyan-Dent [États-Unis] ; Barbara B. Bendlin [États-Unis] ; Sandra J. Harding [États-Unis] ; Charles K. Stone [États-Unis] ; Barb Mueller [États-Unis] ; Sterling C. Johnson [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2011-09.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Aged, Brain (radionuclide imaging), Comparative study, Dihydroxyphenylalanine (analogs & derivatives), Dihydroxyphenylalanine (diagnostic use), Dihydroxyphenylalanine (pharmacokinetics), Dopamine, Emission tomography, Female, Fluorine Radioisotopes (diagnostic use), Fluorodopa (18F), Human, Humans, Levodopa, Male, Metabolism, Middle Aged, Nervous system diseases, Parkinson Disease (pathology), Parkinson Disease (radionuclide imaging), Parkinson disease, Parkinson's disease/radionuclide imaging, Positron emission tomography, Severity of Illness Index, Tomography, Emission-Computed, Tyrosine, Tyrosine (analogs & derivatives), Tyrosine (diagnostic use), Tyrosine (pharmacokinetics), dopamine/metabolism, positron emission tomography.
- MESH :
- chemical , analogs & derivatives : Dihydroxyphenylalanine, Tyrosine.
- chemical , diagnostic use : Dihydroxyphenylalanine, Fluorine Radioisotopes, Tyrosine.
- chemical , pharmacokinetics : Dihydroxyphenylalanine, Tyrosine.
- pathology : Parkinson Disease.
- radionuclide imaging : Brain, Parkinson Disease.
- Aged, Female, Humans, Male, Middle Aged, Severity of Illness Index, Tomography, Emission-Computed.
Abstract
Progression of Parkinson's disease symptoms is imperfectly correlated with positron emission tomography biomarkers for dopamine biosynthetic pathways. The radiopharmaceutical 6‐[18F]fluoro‐m‐tyrosine is not a substrate for catechol‐O‐methyltransferase and therefore has a more favorable uptake‐to‐background ratio than 6‐[18F]fluoro‐L‐dopa. The objective of this study was to evaluate 6‐[18F]fluoro‐m‐tyrosine relative to 6‐[18F]fluoro‐L‐dopa with partial catechol‐O‐methyltransferase inhibition as a biomarker for clinical status in Parkinson's disease. Twelve patients with early‐stage Parkinson's disease, off medication, underwent Unified Parkinson Disease Rating Scale scoring, brain magnetic resonance imaging, and 3‐dimensional dynamic positron emission tomography using equivalent doses of 6‐[18F]fluoro‐m‐tyrosine and 6‐[18F]fluoro‐L‐dopa with tolcapone, a catechol‐O‐methyltransferase inhibitor. Images were realigned within subject, after which the tissue‐derived uptake rate constant was generated for volumes of interest encompassing the caudate nucleus, putamen, and subregions of the putamen. We computed both bivariate (Pearson) and partial (covariate of age) correlations between clinical subscores and tissue‐derived uptake rate constant. Tissue‐derived uptake rate constant values were correlated between the radiopharmaceuticals (r = 0.8). Motor subscores were inversely correlated with the contralateral putamen 6‐[18F]fluoro‐m‐tyrosine tissue‐derived uptake rate constant (|r| > 0.72, P < .005) but not significantly with the 6‐[18F]fluoro‐L‐dopa tissue‐derived uptake rate constant. The uptake rate constants for both radiopharmaceuticals were also inversely correlated with activities of daily living subscores, but the magnitude of correlation coefficients was greater for 6‐[18F]fluoro‐m‐tyrosine. In this design, 6‐[18F]fluoro‐m‐tyrosine uptake better reflected clinical status than did 6‐[18F]fluoro‐L‐dopa uptake. We attribute this finding to 6‐[18F]fluoro‐m‐tyrosine's higher affinity for the target, L‐aromatic amino acid decarboxylase, and the absence of other major determinants of the uptake rate constant. These results also imply that L‐aromatic amino acid decarboxylase activity is a major determinant of clinical status. © 2011 Movement Disorder Society
Url:
- https://api.istex.fr/document/522EE64365D119496B962B5766EE5C0A818FA428/fulltext/pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278160
DOI: 10.1002/mds.23778
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000929
- to stream Istex, to step Curation: 000929
- to stream Istex, to step Checkpoint: 000562
- to stream Pmc, to step Corpus: 000157
- to stream Pmc, to step Curation: 000157
- to stream Pmc, to step Checkpoint: 000289
- to stream PubMed, to step Corpus: 001149
- to stream PubMed, to step Curation: 001149
- to stream PubMed, to step Checkpoint: 001494
- to stream Ncbi, to step Merge: 003279
- to stream Ncbi, to step Curation: 003279
- to stream Ncbi, to step Checkpoint: 003279
- to stream Main, to step Merge: 001883
- to stream PascalFrancis, to step Corpus: 000421
- to stream PascalFrancis, to step Curation: 002897
- to stream PascalFrancis, to step Checkpoint: 000730
- to stream Main, to step Merge: 001D20
- to stream Main, to step Curation: 001829
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A within‐subject comparison of 6‐[18F]fluoro‐m‐tyrosine and 6‐[18F]fluoro‐L‐dopa in Parkinson's disease</title>
<author><name sortKey="Gallagher, Catherine L" sort="Gallagher, Catherine L" uniqKey="Gallagher C" first="Catherine L." last="Gallagher">Catherine L. Gallagher</name>
</author>
<author><name sortKey="Christian, Bradley T" sort="Christian, Bradley T" uniqKey="Christian B" first="Bradley T." last="Christian">Bradley T. Christian</name>
</author>
<author><name sortKey="Holden, James E" sort="Holden, James E" uniqKey="Holden J" first="James E." last="Holden">James E. Holden</name>
</author>
<author><name sortKey="Dejesus, Onofre T" sort="Dejesus, Onofre T" uniqKey="Dejesus O" first="Onofre T." last="Dejesus">Onofre T. Dejesus</name>
</author>
<author><name sortKey="Nickles, Robert J" sort="Nickles, Robert J" uniqKey="Nickles R" first="Robert J." last="Nickles">Robert J. Nickles</name>
</author>
<author><name sortKey="Buyan Ent, Laura" sort="Buyan Ent, Laura" uniqKey="Buyan Ent L" first="Laura" last="Buyan-Dent">Laura Buyan-Dent</name>
</author>
<author><name sortKey="Bendlin, Barbara B" sort="Bendlin, Barbara B" uniqKey="Bendlin B" first="Barbara B." last="Bendlin">Barbara B. Bendlin</name>
</author>
<author><name sortKey="Harding, Sandra J" sort="Harding, Sandra J" uniqKey="Harding S" first="Sandra J." last="Harding">Sandra J. Harding</name>
</author>
<author><name sortKey="Stone, Charles K" sort="Stone, Charles K" uniqKey="Stone C" first="Charles K." last="Stone">Charles K. Stone</name>
</author>
<author><name sortKey="Mueller, Barb" sort="Mueller, Barb" uniqKey="Mueller B" first="Barb" last="Mueller">Barb Mueller</name>
</author>
<author><name sortKey="Johnson, Sterling C" sort="Johnson, Sterling C" uniqKey="Johnson S" first="Sterling C." last="Johnson">Sterling C. Johnson</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:522EE64365D119496B962B5766EE5C0A818FA428</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1002/mds.23778</idno>
<idno type="url">https://api.istex.fr/document/522EE64365D119496B962B5766EE5C0A818FA428/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000929</idno>
<idno type="wicri:Area/Istex/Curation">000929</idno>
<idno type="wicri:Area/Istex/Checkpoint">000562</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Gallagher C:a:within:subject</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278160</idno>
<idno type="RBID">PMC:3278160</idno>
<idno type="wicri:Area/Pmc/Corpus">000157</idno>
<idno type="wicri:Area/Pmc/Curation">000157</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000289</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">001149</idno>
<idno type="wicri:Area/PubMed/Curation">001149</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001494</idno>
<idno type="wicri:Area/Ncbi/Merge">003279</idno>
<idno type="wicri:Area/Ncbi/Curation">003279</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003279</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Gallagher C:a:within:subject</idno>
<idno type="wicri:Area/Main/Merge">001883</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:11-0444599</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000421</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002897</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000730</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Gallagher C:a:within:subject</idno>
<idno type="wicri:Area/Main/Merge">001D20</idno>
<idno type="wicri:Area/Main/Curation">001829</idno>
<idno type="wicri:Area/Main/Exploration">001829</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A within‐subject comparison of 6‐[18F]fluoro‐m‐tyrosine and 6‐[18F]fluoro‐L‐dopa in Parkinson's disease</title>
<author><name sortKey="Gallagher, Catherine L" sort="Gallagher, Catherine L" uniqKey="Gallagher C" first="Catherine L." last="Gallagher">Catherine L. Gallagher</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>William S. Middleton Veterans Hospital, Madison, Wisconsin</wicri:regionArea>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin</wicri:regionArea>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Christian, Bradley T" sort="Christian, Bradley T" uniqKey="Christian B" first="Bradley T." last="Christian">Bradley T. Christian</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Wisconsin, Department of Medical Physics, Madison, Wisconsin</wicri:regionArea>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Waisman Laboratory for Brain Imaging and Behavior, Madison, Wisconsin</wicri:regionArea>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Holden, James E" sort="Holden, James E" uniqKey="Holden J" first="James E." last="Holden">James E. Holden</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Wisconsin, Department of Medical Physics, Madison, Wisconsin</wicri:regionArea>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dejesus, Onofre T" sort="Dejesus, Onofre T" uniqKey="Dejesus O" first="Onofre T." last="Dejesus">Onofre T. Dejesus</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Wisconsin, Department of Medical Physics, Madison, Wisconsin</wicri:regionArea>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nickles, Robert J" sort="Nickles, Robert J" uniqKey="Nickles R" first="Robert J." last="Nickles">Robert J. Nickles</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Wisconsin, Department of Medical Physics, Madison, Wisconsin</wicri:regionArea>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Buyan Ent, Laura" sort="Buyan Ent, Laura" uniqKey="Buyan Ent L" first="Laura" last="Buyan-Dent">Laura Buyan-Dent</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin</wicri:regionArea>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bendlin, Barbara B" sort="Bendlin, Barbara B" uniqKey="Bendlin B" first="Barbara B." last="Bendlin">Barbara B. Bendlin</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>William S. Middleton Veterans Hospital G.R.E.C.C., Madison, Wisconsin</wicri:regionArea>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin</wicri:regionArea>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Harding, Sandra J" sort="Harding, Sandra J" uniqKey="Harding S" first="Sandra J." last="Harding">Sandra J. Harding</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>William S. Middleton Veterans Hospital G.R.E.C.C., Madison, Wisconsin</wicri:regionArea>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin</wicri:regionArea>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Stone, Charles K" sort="Stone, Charles K" uniqKey="Stone C" first="Charles K." last="Stone">Charles K. Stone</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin</wicri:regionArea>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mueller, Barb" sort="Mueller, Barb" uniqKey="Mueller B" first="Barb" last="Mueller">Barb Mueller</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Waisman Laboratory for Brain Imaging and Behavior, Madison, Wisconsin</wicri:regionArea>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Johnson, Sterling C" sort="Johnson, Sterling C" uniqKey="Johnson S" first="Sterling C." last="Johnson">Sterling C. Johnson</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>William S. Middleton Veterans Hospital G.R.E.C.C., Madison, Wisconsin</wicri:regionArea>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin</wicri:regionArea>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2011-09">2011-09</date>
<biblScope unit="vol">26</biblScope>
<biblScope unit="issue">11</biblScope>
<biblScope unit="page" from="2032">2032</biblScope>
<biblScope unit="page" to="2038">2038</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">522EE64365D119496B962B5766EE5C0A818FA428</idno>
<idno type="DOI">10.1002/mds.23778</idno>
<idno type="ArticleID">MDS23778</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Brain (radionuclide imaging)</term>
<term>Comparative study</term>
<term>Dihydroxyphenylalanine (analogs & derivatives)</term>
<term>Dihydroxyphenylalanine (diagnostic use)</term>
<term>Dihydroxyphenylalanine (pharmacokinetics)</term>
<term>Dopamine</term>
<term>Emission tomography</term>
<term>Female</term>
<term>Fluorine Radioisotopes (diagnostic use)</term>
<term>Fluorodopa (18F)</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Male</term>
<term>Metabolism</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (pathology)</term>
<term>Parkinson Disease (radionuclide imaging)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease/radionuclide imaging</term>
<term>Positron emission tomography</term>
<term>Severity of Illness Index</term>
<term>Tomography, Emission-Computed</term>
<term>Tyrosine</term>
<term>Tyrosine (analogs & derivatives)</term>
<term>Tyrosine (diagnostic use)</term>
<term>Tyrosine (pharmacokinetics)</term>
<term>dopamine/metabolism</term>
<term>positron emission tomography</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Dihydroxyphenylalanine</term>
<term>Tyrosine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Dihydroxyphenylalanine</term>
<term>Fluorine Radioisotopes</term>
<term>Tyrosine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Dihydroxyphenylalanine</term>
<term>Tyrosine</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Brain</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Severity of Illness Index</term>
<term>Tomography, Emission-Computed</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dopamine</term>
<term>Etude comparative</term>
<term>Fluorodopa (18F)</term>
<term>Homme</term>
<term>Lévodopa</term>
<term>Maladie de Parkinson</term>
<term>Métabolisme</term>
<term>Pathologie du système nerveux</term>
<term>Tomographie par émission de positons</term>
<term>Tomoscintigraphie</term>
<term>Tyrosine</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Progression of Parkinson's disease symptoms is imperfectly correlated with positron emission tomography biomarkers for dopamine biosynthetic pathways. The radiopharmaceutical 6‐[18F]fluoro‐m‐tyrosine is not a substrate for catechol‐O‐methyltransferase and therefore has a more favorable uptake‐to‐background ratio than 6‐[18F]fluoro‐L‐dopa. The objective of this study was to evaluate 6‐[18F]fluoro‐m‐tyrosine relative to 6‐[18F]fluoro‐L‐dopa with partial catechol‐O‐methyltransferase inhibition as a biomarker for clinical status in Parkinson's disease. Twelve patients with early‐stage Parkinson's disease, off medication, underwent Unified Parkinson Disease Rating Scale scoring, brain magnetic resonance imaging, and 3‐dimensional dynamic positron emission tomography using equivalent doses of 6‐[18F]fluoro‐m‐tyrosine and 6‐[18F]fluoro‐L‐dopa with tolcapone, a catechol‐O‐methyltransferase inhibitor. Images were realigned within subject, after which the tissue‐derived uptake rate constant was generated for volumes of interest encompassing the caudate nucleus, putamen, and subregions of the putamen. We computed both bivariate (Pearson) and partial (covariate of age) correlations between clinical subscores and tissue‐derived uptake rate constant. Tissue‐derived uptake rate constant values were correlated between the radiopharmaceuticals (r = 0.8). Motor subscores were inversely correlated with the contralateral putamen 6‐[18F]fluoro‐m‐tyrosine tissue‐derived uptake rate constant (|r| > 0.72, P < .005) but not significantly with the 6‐[18F]fluoro‐L‐dopa tissue‐derived uptake rate constant. The uptake rate constants for both radiopharmaceuticals were also inversely correlated with activities of daily living subscores, but the magnitude of correlation coefficients was greater for 6‐[18F]fluoro‐m‐tyrosine. In this design, 6‐[18F]fluoro‐m‐tyrosine uptake better reflected clinical status than did 6‐[18F]fluoro‐L‐dopa uptake. We attribute this finding to 6‐[18F]fluoro‐m‐tyrosine's higher affinity for the target, L‐aromatic amino acid decarboxylase, and the absence of other major determinants of the uptake rate constant. These results also imply that L‐aromatic amino acid decarboxylase activity is a major determinant of clinical status. © 2011 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Wisconsin</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Wisconsin"><name sortKey="Gallagher, Catherine L" sort="Gallagher, Catherine L" uniqKey="Gallagher C" first="Catherine L." last="Gallagher">Catherine L. Gallagher</name>
</region>
<name sortKey="Bendlin, Barbara B" sort="Bendlin, Barbara B" uniqKey="Bendlin B" first="Barbara B." last="Bendlin">Barbara B. Bendlin</name>
<name sortKey="Bendlin, Barbara B" sort="Bendlin, Barbara B" uniqKey="Bendlin B" first="Barbara B." last="Bendlin">Barbara B. Bendlin</name>
<name sortKey="Buyan Ent, Laura" sort="Buyan Ent, Laura" uniqKey="Buyan Ent L" first="Laura" last="Buyan-Dent">Laura Buyan-Dent</name>
<name sortKey="Christian, Bradley T" sort="Christian, Bradley T" uniqKey="Christian B" first="Bradley T." last="Christian">Bradley T. Christian</name>
<name sortKey="Christian, Bradley T" sort="Christian, Bradley T" uniqKey="Christian B" first="Bradley T." last="Christian">Bradley T. Christian</name>
<name sortKey="Dejesus, Onofre T" sort="Dejesus, Onofre T" uniqKey="Dejesus O" first="Onofre T." last="Dejesus">Onofre T. Dejesus</name>
<name sortKey="Gallagher, Catherine L" sort="Gallagher, Catherine L" uniqKey="Gallagher C" first="Catherine L." last="Gallagher">Catherine L. Gallagher</name>
<name sortKey="Harding, Sandra J" sort="Harding, Sandra J" uniqKey="Harding S" first="Sandra J." last="Harding">Sandra J. Harding</name>
<name sortKey="Harding, Sandra J" sort="Harding, Sandra J" uniqKey="Harding S" first="Sandra J." last="Harding">Sandra J. Harding</name>
<name sortKey="Holden, James E" sort="Holden, James E" uniqKey="Holden J" first="James E." last="Holden">James E. Holden</name>
<name sortKey="Johnson, Sterling C" sort="Johnson, Sterling C" uniqKey="Johnson S" first="Sterling C." last="Johnson">Sterling C. Johnson</name>
<name sortKey="Johnson, Sterling C" sort="Johnson, Sterling C" uniqKey="Johnson S" first="Sterling C." last="Johnson">Sterling C. Johnson</name>
<name sortKey="Mueller, Barb" sort="Mueller, Barb" uniqKey="Mueller B" first="Barb" last="Mueller">Barb Mueller</name>
<name sortKey="Nickles, Robert J" sort="Nickles, Robert J" uniqKey="Nickles R" first="Robert J." last="Nickles">Robert J. Nickles</name>
<name sortKey="Stone, Charles K" sort="Stone, Charles K" uniqKey="Stone C" first="Charles K." last="Stone">Charles K. Stone</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001829 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001829 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:522EE64365D119496B962B5766EE5C0A818FA428 |texte= A within‐subject comparison of 6‐[18F]fluoro‐m‐tyrosine and 6‐[18F]fluoro‐L‐dopa in Parkinson's disease }}
This area was generated with Dilib version V0.6.23. |